表紙
市場調查報告書

人遺傳基因定序市場 - 策略,趨勢,預測:2020年∼2024年

Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024

出版商 Howe Sound Research 商品編碼 943731
出版日期 內容資訊 英文 549 Pages
商品交期: 最快1-2個工作天內
價格
人遺傳基因定序市場 - 策略,趨勢,預測:2020年∼2024年 Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024
出版日期: 2020年06月21日內容資訊: 英文 549 Pages
簡介

本報告提供全球人遺傳基因定序市場相關調查分析,市場概要,市場趨勢,最近的開發,主要企業等相關的系統性資訊。

目錄

第1章 簡介與市場定義

第2章 市場概要

  • 發揮各種作用的市場參與企業
  • 人遺傳基因定序:市場,案例,討論
  • 產業結構

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 定序儀器

第4章 人的遺傳基因定序的最近的開發

  • 最近的開發
  • 開發的重要性
  • 使用方法
    • Yourgene Health
    • NorthShore
    • Germline
    • FDA
    • BillionToOne
    • Mass General, Brigham and Women's Open Clinics
    • Asuragen Fragile
    • Fluxion Bio等

第5章 主要企業的簡介

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Cepheid (now Danaher
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

第6章 全球人類基因圖譜定序市場

  • 全球市場概要:各國
  • 全球市場:各用途 - 概要

第7章 市場規模:各用途

  • 遺傳性遺傳基因定序市場
  • 新生兒遺傳基因定序市場
  • NIPT遺傳基因定序市場
  • 癌症遺傳基因定序市場
  • 藥理基因學遺傳基因定序市場
  • D2C遺傳基因定序市場

第8章 人遺傳基因定序的未來願景

目錄

OVERVIEW:

Will all newborns receive genetic testing at birth? Why has Direct to Consumer Testing taken a big jump? What's holding the industry back? Where are the over 800 locations that have high throughput sequencing devices?

Our facts and support = Your success.

The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Gene Sequencing Definition In This Report
    • 1.1.1. Gene Sequencing
    • 1.1.2. Hereditary
    • 1.1.3. Newborn Screening
    • 1.1.4. Non Invasise Prenatal Testing
    • 1.1.5. Oncology
    • 1.1.6. Pharmacogenomic
    • 1.1.7. Direct to Consumer
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for laboratory testing
  • 1.5. Genetic Testing vs. Gene Sequencing
    • 1.5.1. Cost and Pricing Practice
  • 1A. Global Listing of Sequencer Installed Base - Location & Contacts
    • 1A.1. Notes to Installed Base Listing

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Instrument Manufacturer
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Sequencing Labs
    • 2.1.10. Audit body
  • 2.2. Human Gene Sequencing -Markets, Examples and Discussion
    • 2.2.1. Inherited Disease - Not what it used to be
      • 2.2.1.1. Clinical and Research Lines Blur
      • 2.2.1.2. Genetic Counselling - Not so simple anymore
      • 2.2.1.3. The Genetic Blizzard - Issues of Access and Payment
    • 2.2.2. Newborn Screening - The Standard of Care
      • 2.2.2.1. Newborn Screening - Do Parents Want to Know?
    • 2.2.3. NIPT - We've Only Just Begun
      • 2.2.3.1. NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
      • 2.2.3.2. NIPT in the Future - Beyond Inherited Disease
    • 2.2.4. Oncology - Understanding Two Worlds
      • 2.2.4.1. The Tumor - A Sequence of Sequencing
      • 2.2.4.2. The Tumor - Biopsy and Liquid Biopsy
      • 2.2.4.3. The Human Genome - Predisposition and Prognosis
    • 2.2.5. Pharmacogenomics
      • 2.2.5.1. Sequencing Not the Only Player
      • 2.2.5.2. New Roles for Old Drugs - A Research Bonanza?
    • 2.2.6. Direct To Consumer - More Than Meets the Eye
      • 2.2.6.1. DTC - How Many Segments?
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. The Rise of the Sequencing Lab
    • 2.3.3. Sequencing as a Commodity
    • 2.3.4. Informatics
    • 2.3.5. Instrument Manufacturer Role
    • 2.3.6. Healthcare Industry Impacts - Still Struggling
    • 2.3.7. Can the Healthcare Industry Adapt?
    • 2.3.8. Genetic Counselling as an Industry
    • 2.3.9. Sequencing Adoption and Cannibalization

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. New Diagnoses
    • 3.1.2. Wellness and Prevention
    • 3.1.3. Fertility Technology
    • 3.1.4. Cancer - Screening, Management and Monitoring
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Healthcare Cost Concerns Curtail Growth.
    • 3.2.4. Wellness has a downside
  • 3.3. Sequencing Instrumentation
    • 3.3.1. Instrumentation Tenacity.
    • 3.3.2. Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3. LISTING of CURRENT INSTRUMENT SPECIFICATIONS
    • 3.3.4. Long Reads - Further Segmentation
    • 3.3.5. Linked Reads
    • 3.3.6. New Sequencing Technologies

4. Human Gene Sequencing Recent Developments

  • 4.1. Recent Developments - Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Yourgene Health Gets CE Mark for Iona NIPT Test
      • NorthShore Looks to Expand Genomics Integration Into Primary Care
      • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients
      • FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
      • BillionToOne Closes $15M Series A Follow-on Round
      • Mass General, Brigham and Women's Open Clinics to Integrate Genomics Into Primary Care
      • Asuragen Fragile X Diagnostic Test Gets FDA Authorization
      • Fluxion Bio Wins NIH Grant to Develop NIPT Assay
      • Illumina, Broad Institute Collaborate on Genome Analysis Software
      • Illumina, Adaptive Biotechnologies Partner on IVD Test Kits for Immune Sequencing
      • Menarini Silicon Biosystems, BlueBee Partner on Sequencing Data Analysis Platform
      • Paying cash for elective genomic sequencing
      • NIH funds Color ahead of million-person sequencing effort
      • Veritas Genetics slashes price of whole genome sequencing 40% to $600
      • Superfast gene sequencing diagnoses critically ill patients
      • Veracyte Details Clinical Utility of RNA Sequencing-Based Testing for Thyroid Cancer
      • Longas Technologies Launches. Offers 'Virtual Long Read' Library Prep
      • New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
      • PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive
      • Health Management
      • Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests
      • PGDx and PathGroup Enter Co-Development Agreement
      • Newborn genomic sequencing detects unanticipated disease risk factors

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Cepheid (now Danaher
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. The Global Market for Human Genome Sequencing

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table - Global Market by Country
    • 6.1.2. Chart - Global Market by Country
  • 6.2. Global Market by Application - Overview
    • 6.2.1. Table - Global Market by Application
    • 6.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 6.2.3. Chart - Global Market by Application - Base Year
    • 6.2.4. Chart - Global Market by Application - Final Year
    • 6.2.5. Chart - Global Market by Application - Share by Year
    • 6.2.6. Chart - Global Market by Application - Segment Growth

7. Market Sizes by Application

  • 7.1. Hereditary Gene Sequencing Market
  • 7.2. Newborn Gene Sequencing Market
  • 7.3. NIPT Gene Sequencing Market
  • 7.4. Oncology Gene Sequencing Market
  • 7.5. Pharmacogenomic Gene Sequencing Market
  • 7.6. Direct To Consumer Gene Sequencing Market

8. Vision of the Future of Human Gene Sequencing

Appendices

I. United States Medicare System: January 2020 laboratory Fees Schedule

II. The Whole Genome Sequence of SARS-CoV-2

III. Methodology

  • II.1. Authors
  • II.2. Sources

II. Methodology

  • II.1. Authors
  • II.2. Sources

Table of Tables

  • Table 1: The Base Pairs
  • Table 2: Most Common Traditional Genetic Disorders
  • Table 3: Lab Spending 2014 to 2024
  • Table 4: List of GLOBAL SEQUENCING LOCATIONS
  • Table 5: Market Players by Type
  • Table 6: The Different Markets for Human Gene Sequencing
  • Table 7: DTC Sub Segments
  • Table 8: The Factors Driving Growth
  • Table 9: Factors Limiting Growth
  • Table 10: - Listing of Current NGS Instrument Specifications
  • Table 11: Six New Sequencing Technologies
  • Table 12: - Global Market by Region
  • Table 13: Global Market by Application
  • Table 14: Hereditary Segment by Country
  • Table 15: Newborn Segment by Country
  • Table 16: NIPT Segment by Country
  • Table 17: Oncology Segment by Country
  • Table 18: Pharmacogenomic Segment by Country
  • Table 19: Direct To Consumer Segment by Country
  • Table 20: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Gene Sequencing
  • Figure 3: TruSight Germline Panel
  • Figure 4: Historical Cost of Gene Sequencing
  • Figure 5: - Cost To Sequence a Human Genome
  • Figure 6: Base Year Country Market Share Chart
  • Figure 7: Global Market by Application - Base vs. Final Year
  • Figure 8: Global Market by Application Base Year
  • Figure 9: Global Market by Application Final Year
  • Figure 10: Application Type Share by Year
  • Figure 11: by Application Segment Growth
  • Figure 12: Hereditary vs. Total Market Growth
  • Figure 13: Newborn vs. Total Market Growth
  • Figure 14: NIPT vs. Total Market Growth
  • Figure 15: Oncology vs. Total Market Growth
  • Figure 16: Pharmacogenomic vs. Total Market Growth
  • Figure 17: Direct To Consumer vs. Total Market Growth